

**TEST STATUS****NOTIFICATION DATE:** April 24, 2017**EFFECTIVE DATE:** May 24, 2107**NEUROMYELITIS OPTICA (NMO)/AQUAPORIN-4-IGG CELL-BINDING  
ASSAY, CSF**  
**Test ID: NMOCC**

**NOTE:** New York State Clients will continue to receive NMOCC - Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Cell-Binding Assay, CSF, as a replacement for NMOFC - Neuromyelitis Optica (NMO)/Aquaporin-4-IgG Fluorescence-Activated Cell Sorting (FACS) Assay.

We are actively working to provide the New York State Department of Health with the additional information that is being requested. An update will be provided once we are able to resume New York client testing.

The new tests recently announced will utilize Test ID: NMOCC as a possible reflex if IFA pattern suggest NMO/AQP4-IgG. The tests affected are listed below.

**ENC1 – ENCEPHALOPATHY, AUTOIMMUNE EVALUATION, CSF (REPLACES ENCEC)**

**DMC1 - DEMENTIA, AUTOIMMUNE EVALUATION, CSF (REPLACES DEMEC)**

**EPC1 – EPILEPSY, AUTOIMMUNE EVALUATION, CSF (REPLACES EPIEC)**

**PAC1 - PARANEOPLASTIC AUTOANTIBODY EVALUATION, CSF**

**METHODOLOGY:** Cell-Binding Assay (CBA) detects IgG specific for AQP4 (M1 isoform) by Indirect Immunofluorescence (IFA)

**REFERENCE VALUES:** Negative

**CPT CODE:** 86255